Avatrombopag 20 mg Oral Tablet

DRUG5 trials

Sponsors

Sobi, Inc., Institute of Hematology & Blood Diseases Hospital, China, Al-Mustansiriyah University, Shanghai Zhongshan Hospital, Swedish Orphan Biovitrum

Conditions

Aplastic AnemiaITP - Immune ThrombocytopeniaImmune ThrombocytopeniaLiver TransplanatationPostoperative ComplicationSevere Thrombocytopenia

Phase 2

A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment

Not yet recruitingNCT07786922

Swedish Orphan BiovitrumAplastic Anemia

Start: 2026-07-31End: 2029-12-31Target: 26Updated: 2026-08-26

Phase 3

Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

WithdrawnNCT05046327

Sobi, Inc.Immune Thrombocytopenia

Start: 2021-10-14End: 2025-02-19Updated: 2021-10-22

Phase 4

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

RecruitingNCT07133659

Al-Mustansiriyah UniversityITP - Immune Thrombocytopenia

Start: 2025-06-08End: 2027-07-08Target: 25Updated: 2025-08-21

Unknown Phase

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

Institute of Hematology & Blood Diseases Hospital, ChinaAplastic Anemia

Start: 2022-06-28End: 2024-06-28Target: 39Updated: 2022-10-07

Avatrombopag for Severe Thrombocytopenia After Liver Transplantation: A Retrospective Cohort Study

CompletedNCT07600905

Shanghai Zhongshan HospitalLiver Transplanatation, Postoperative Complication, Severe Thrombocytopenia

Start: 2019-11-01End: 2025-08-31Updated: 2026-08-28